|
業務類別
|
Biotechnology |
|
業務概覽
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
| 公司地址
| 50 Broadway, 7th Floor, London, GBR, SW1H 0BD |
| 電話號碼
| +44 2074003347 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.roivant.com |
| 員工數量
| 750 |
| Mr. Richard Pulik |
Chief Financial Officer |
美元 437.75K |
29/07/2025 |
| Dr. Mayukh Sukhatme |
Co-President, Chief Investment Officer and Director |
美元 550.00K |
29/07/2025 |
| Mr. Matthew Gline |
Chief Executive Officer and Director |
美元 725.00K |
29/07/2025 |
| Dr. Eric Venker, M.D.,Pharm.D. |
Co-President; Chief Executive Officer, Immunovant |
美元 600.21K |
29/07/2025 |
| Dr. Frank M. Torti, M.D. |
Co-President |
-- |
29/07/2025 |
| Ms. Jennifer Humes |
Chief Accounting Officer; Chief Accounting Officer of RSI |
美元 41.90K |
29/07/2025 |
|
|
| Dr. Mayukh Sukhatme |
Co-President, Chief Investment Officer and Director |
29/07/2025 |
| Mr. Matthew Gline |
Chief Executive Officer and Director |
29/07/2025 |
| Mr. Daniel Gold |
Independent Director |
29/07/2025 |
| Ms. Melissa B. Epperly |
Independent Director |
29/07/2025 |
| Mr. Ilan Oren |
Chairman of the Board |
29/07/2025 |
| Mr. Keith Manchester, M.D. |
Independent Director |
29/07/2025 |
| Mr. James C. Momtazee |
Independent Director |
29/07/2025 |
| Dr. Meghan M. Fitzgerald, Ph. |
Independent Director |
29/07/2025 |
|
|
|
|
